Collectively, our results indicate that CyH suppresses EMT and cancer stemness in NSCLC cells, suggesting that CyH may be a potential chemotherapeutic agent in NSCLC therapy. The gene discussed is CMA1; the disease is non-small cell lung carcinoma.